Organovo reports ~$11.3M cash, expects to meet Nasdaq listing requirements

VivoSim Labs, INC.

Preliminary cash and equivalents ~$11.3M as of March 31, 2025; Q4 net cash utilization ~$2.0M-$2.2M.
Stock closed above $1.00 minimum bid since March 21, 2025; company expects to meet continued listing criteria.
Hearings Panel granted exception until April 15, 2025 to demonstrate compliance with bid price and equity rules.
Believes it meets $2.5M stockholders' equity after $9M upfront from FXR asset sale to Eli Lilly.
Expects potential $5M milestone within 12 months from FXR program upon Phase 2 trial commencement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.